Aurora Cannabis Accelerates International Medical Cannabis Business Expansion

Aurora Cannabis reported increased international medical cannabis revenues in its first quarter of fiscal 2027, marking a strategic shift toward global markets despite lower overall revenue and adjusted EBITDA. The company's focus on international medical cannabis expansion reflects growing demand for regulated therapeutic cannabis products worldwide. This development is significant for patients in jurisdictions like Puerto Rico seeking access to standardized, quality-controlled medical cannabis treatments for conditions such as chronic pain, anxiety, and epilepsy. Aurora's international growth strategy could improve availability and accessibility of medical-grade cannabis products in underserved markets. The company's business restructuring demonstrates the maturing medical cannabis industry's move toward sustainable, patient-centered operations.